Everything below concerns anti-doping. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-04-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
=== Exercise === A controlled exercise program combats atherosclerosis by improving the circulation and blood vessel functionality. Exercise is also used to manage weight in patients who are obese, lower blood pressure, and decrease cholesterol. Often, lifestyle modification is combined with medication therapy. For example, statins help to lower cholesterol. Antiplatelet medications like aspirin help to prevent clots, and a variety of antihypertensive medications are routinely used to control blood pressure. If the combined efforts of risk factor modification and medication therapy are not sufficient to control symptoms or fight imminent threats of ischemic events, a physician may resort to interventional or surgical procedures to correct the obstruction.
The renal interstitium facilitates solute and water transport between blood and urine in the vascular and tubular elements of the kidneys, and water reabsorption through changes in solute concentrations and hydrostatic gradients. The myocardial interstitium participates in ionic exchanges associated with the spread of electrical events. The pulmonary interstitium allows for fluctuations in lung volume between inspiration and expiration. The composition and chemical properties of the interstitial fluid vary among organs and undergo changes in chemical composition during normal function, as well as during body growth, conditions of inflammation, and development of diseases, as in heart failure and chronic kidney disease.
For example, for decays of 132Cs, 98.13% are ε (electron capture) or β+ (positron) decays, and 1.87% are β− (electron) decays. The half-life of this isotope is 6.480 days, which corresponds to a total decay constant of 0.1070 d−1. Then the partial decay constants, as computed from the branching fractions, are 0.1050 d−1 for ε/β+ decays, and 2.001×10−3 d−1 for β− decays. Their respective partial half-lives are 6.603 d and 347 d. Isotopes with significant branching of decay modes include copper-64, arsenic-74, rhodium-102, indium-112, iodine-126 and holmium-164.
=== Israel === Israel declared a nationwide state of emergency, saying that the strikes on Iran were the largest that it had ever launched. Israeli schools and workspaces were closed and public gatherings were canceled. In the 40 days from the start of the war through the 8 April ceasefire, there were a total of 650 missile attacks from Iran to Israel, the majority of which carried cluster munitions. About 16 of the missiles that made it past Israeli missile defenses carried conventional warheads, while 50 had cluster munitions. The attacks killed a total of 24 people, all of them civilians, and resulted in more than 7,000 injuries. Of the 24 civilians killed, 14 were struck by conventional explosive warheads and 10 by cluster submunitions. Two of the deaths were inside a sheltered space, with the other fatalities being people in unprotected areas.
Sources: en.wikipedia.org
The hemolymph, pericardial fluid and urine of cephalopods, including the common octopus, are all isosmotic with each other, as well as with the surrounding sea water. It has been suggested that cephalopods do not osmoregulate, which would indicate that they are conformers. This means that they adapt to match the osmotic pressure of their environment, and because there is no osmotic gradient, there is no net movement of water from the organism to the seawater, or from the seawater into the organism. Octopuses have an average minimum salinity requirement of 27 g/L (0.00098 lb/cu in), and that any disturbance introducing significant amounts of fresh water into their environment can prove fatal. In terms of ions, however, a discrepancy does seem to occur between ionic concentrations found in the seawater and those found within cephalopods. In general, they seem to maintain hypoionic concentrations of sodium, calcium, and chloride in contrast to the salt water. Sulfate and potassium exist in a hypoionic state, as well, with the exception of the excretory systems of cephalopods, where the urine is hyperionic. These ions are free to diffuse, and because they exist in hypoionic concentrations within the organism, they would be moving into the organism from the seawater. The fact that the organism can maintain hypoionic concentrations suggests not only that a form of ionic regulation exists within cephalopods, but also that they also actively excrete certain ions such as potassium and sulfate to maintain homeostasis. O.
668,409 people were registered from administrative databases and could not declare an ethnicity. The proportion of ethnicities in this group is estimated to be the same as the proportion in the declared group.
Overall, the large number of clinical trials carried out on antioxidant supplements suggest that either these products have no effect on health, or that they cause a small increase in mortality in elderly or vulnerable populations.
== Adverse effects == Side effects, although uncommon, include fever, itching, and skin rash when taken by mouth; and red eyes, dry skin, and burning skin when used topically for head lice. It is unclear if the drug is safe for use during pregnancy, but it is probably acceptable for use during breastfeeding. Ivermectin is known to cause severe encephalopathies in some circumstances. Ivermectin is considered relatively free of toxicity in standard doses (around 300 μg/kg). Based on the data drug safety sheet for ivermectin, side effects are uncommon. However, serious adverse events following ivermectin treatment are more common in people with very high burdens of larval Loa loa worms in their blood. Those who have over 30,000 microfilaria per milliliter of blood risk inflammation and capillary blockage due to the rapid death of the microfilaria following ivermectin treatment. One concern is neurotoxicity after large overdoses, which in most mammalian species may manifest as central nervous system depression, ataxia, coma, and death, as might be expected from potentiation of inhibitory chloride channels. Since drugs that inhibit the enzyme CYP3A4 often also inhibit P-glycoprotein transport, the risk of increased absorption past the blood-brain barrier exists when ivermectin is administered along with other CYP3A4 inhibitors. These drugs include statins, HIV protease inhibitors, many calcium channel blockers, lidocaine, benzodiazepines, and glucocorticoids such as dexamethasone. During a typical treatment course, ivermectin can cause minor aminotransferase elevations.
At the same time, the need for such a system was becoming increasingly pressing. In 1932, Winston Churchill and his friend, confidant and scientific advisor Frederick Lindemann travelled by car in Europe, where they saw the rapid rebuilding of the German aircraft industry. It was in November of that year that Stanley Baldwin gave his famous speech, stating that "The bomber will always get through". In the early summer of 1934, the RAF carried out large-scale exercises with up to 350 aircraft. The forces were split, with bombers attempting to attack London, while fighters, guided by the Observer Corps, attempted to stop them. The results were dismal. In most cases, the vast majority of the bombers reached their target without ever seeing a fighter. To address the one-sided results, the RAF gave increasingly accurate information to the defenders, eventually telling the observers where and when the attacks would be taking place. Even then, 70 per cent of the bombers reached their targets unhindered. The numbers suggested any targets in the city would be destroyed. Squadron Leader P. R. Burchall summed up the results by noting that "a feeling of defencelessness and dismay, or at all events of uneasiness, has seized the public." In November, Churchill gave a speech on "The threat of Nazi Germany" in which he pointed out that the Royal Navy could not protect Britain from an enemy who attacked by air. Through the early 1930s, a debate raged within British military and political circles about strategic airpower.
Sources: en.wikipedia.org
=== Personal life and death === Dyson married his first wife, the Swiss mathematician Verena Huber, on 11 August 1950. They had two children, Esther and George, before divorcing in 1958. In November 1958 he married Imme Jung, with whom he had four daughters. Dyson died on 28 February 2020 at Penn Medicine Princeton Medical Center in Plainsboro Township, New Jersey, from complications following a fall. He was 96.
Choh Hao Li (sometimes Cho Hao Li) (Chinese: 李卓皓; pinyin: Lǐ Zhuōhào; April 21, 1913 – November 28, 1987) was a Chinese-born American biochemist who discovered in 1966 that human pituitary growth hormone (somatotropin) consists of a chain of 256 amino acids. In 1970, he succeeded in synthesizing this hormone, the largest protein molecule synthesized up to that time.
== Evolution == The GHR gene is used in animals as a nuclear DNA phylogenetic marker. The exon 10 has first been experienced to explore the phylogeny of the major groups of Rodentia. GHR has also proven useful at lower taxonomic levels, e.g., in octodontoid, arvicoline, muroid, murine, and peromyscine rodents, in arctoid and felid carnivores, and in dermopterans. Note that the GHR intron 9 has also been used to investigate the mustelid and hyaenid carnivores phylogenetics.
doi:10.1016/S0733-8627(05)70156-5. PMID 11130936. Chantelau E., Schiffers T., Schutze J., Hansen B. (1997). "Effect of patient-selected intensive insulin therapy on quality of life". Patient Education and Counseling. 38 (2): 167–713. doi:10.1016/S0738-3991(96)00964-0. PMID 9128618.{{cite journal}}: CS1 maint: multiple names: authors list (link) Crawford L.M., Sinha R.N., Odell R.M., Comi R.J. (2000). "Efficacy of insulin pump therapy: mealtime delivery is the key factor". Endocrine Practice. 6 (3): 239–43. doi:10.4158/EP.6.3.239. PMID 11421538.{{cite journal}}: CS1 maint: multiple names: authors list (link) The DCCT Research Group. JAMA. 1997;227(5):374-4 Skyler J.S. Diabtes Technol Ther. 2000. The DCCT Research Group. Progression of retinopathy with intensive versus conventional treatment in the diabetes control and complications trial. 1994. The DCCT/EDIC Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. NEJM 2005; 353(25): 2643–2653. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus Diabetes Care 2001; 24: 1. Kaufman FR (2001). "A Pilot Study of the Continuous Glucose Monitoring System: Clinical decisions and glycemic control after its use in pediatric type 1 diabetic subjects". Diabetes Care. 24 (12): 2030–4. doi:10.2337/diacare.24.12.2030. PMID 11723078. Floyd J.C., Cornell R.G.; et al. (1993). "A prospective study identifying risk factors for discontinuance of insulin pump therapy".
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.